[1]He D,Du J,Zeng LH,et al.Correlation of Ki67、cerbB-2、p53 and nm23 expression and lymph node metastasis in breast carcinoma[J].Practical Clinical Medicine,2015,16(2):9-10,19.[何丹,杜鹃,曾丽华,等.乳腺癌Ki67、cerbB-2、p53、nm23表达与淋巴结转移的关系[J].实用临床医学,2015,16(2):9-10,19.]
[2]Wang HQ,Gao MH.Expression level of C-erbB-2,Ki67,p53,CA15-3 and AKP in breast cancer patients with bone metastases and its correlation[J].Med Lab Clin,2015,26(1):33-35.[王会琴,高美华.C-erbB-2、Ki67、p53、CA15-3、AKP在乳腺癌骨转移患者中的表达水平及其相关性[J].医学检验与临床,2015,26(1):33-35.]
[3]Sun RN,Zhao YC,Chen JP.Influence factors analysis of rencurrence of breast conserving surgery for breast cancer[J].Modern Instrument & Mediccal Treatment,2015,21(06):65-67.[孙荣能,赵迎春,陈剑平.乳腺癌保乳手术复发影响因素分析[J].现代仪器与医疗,2015,21(06):65-67.]
[4]Liu XD,Li M.Molecular classification of the clinical characteristics of breast cancer[J].Medical Recapitulate,2014,20(12):2148-2150.[刘现栋,李明.乳腺癌的分子分型的临床病理特点[J].医学综述,2014,20(12):2148-2150.]
[5]Ni C,Li T,Wu ZH,et al.Progress on chemotherapy for triple negative breast cancer[J].Chin Oncol,2014,24(4):316-320.[倪晨,李婷,吴振华,等.三阴性乳腺癌化疗进展[J].中国癌症杂志,2014,24(4):316-320.]
[6]Adilijiang·AEK.Differences and clinical significance of ER,PR,HER-2 and Ki-67 status between primary and locally recurrence lesion of breast cancer[J].Xinjiang:Xinjiang Medical University,2016.[阿迪力江·艾尔肯.ER、PR、HER-2、Ki67在乳腺癌原发灶与局部复发灶中表达差异及其临床意义[D].乌鲁木齐:新疆医科大学,2016.]
[7]Dede DS,Gumuskaya B,Guler G,et al.Evaluation of changes in biologic markers ER,PR,HER2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin,yclophosphamide followed by paclitaxel chemotherapy[J].JBUON,2013,18(2):366-371.
[8]Deng ZP,Zhu J,Ma NQ,et al.Discordance of the Expression of ER,PR and Her-2 receptor statuses between primary breast cancer and recurrent focuses[J].Modern Oncology,2011,19(08):1562-1564.[邓智平,朱江,马宁强,等.乳腺癌ER、PR、HER-2在原发灶及复发转移灶中表达变化[J].现代肿瘤医学,2011,19(08):1562-1564.]
[9]Marusyk A,Almendro V,Polyak K.Intra-tumour hetero-genity:a looking glass for cancer[J]?Nat Rev Cancer,2012,12(5):323-334.
[10]Ge WK,Yang B,Zuo WS,et al.Evaluation of breast biopsy to HR,HER-2 and Ki-67 and neoadjuvant chemotherapy's effect on them[J].Chinese J Cancer Prevention and Treament,2014,11(21):847-853.[葛文凯,杨奔,左文述,等.乳腺癌穿刺活检对HR和HER-2及Ki-67评价可靠性以及化疗对其影响研究[J].中华肿瘤防治杂志,2014,11(21):847-853.]
[11]Dieci MV,Criscitiello C,Goubar A,et al.Prognostic value of tumour-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer:a retrospective multicentre study[J].Ann Oncol,2014,25(3):611-618.
[12]Sang D,Wang JY,Xu BH.Pcna Ki67 relations with breast cancer neoadjuvant chemotherapy curative effect[J].China Breast Dis(Electronic Edition),2015,9(1):50-53.[桑蝶,王佳玉,徐兵河.增殖细胞核抗原,Ki67与乳腺癌新辅助化疗疗效的关系[J].中华乳腺癌杂志(电子版),2015,9(1):50-53.]
[13]Chen C,Zhou TY,Wen WR.Expression of Ki67 in breast cancer and its clinical significance:A Meta-analysis[J].J Chinese Oncology,2014,20(04):270-275.[陈崇,周桃玉,温旺荣.乳腺癌组织中Ki67表达及其临床意义的Meta分析[J].肿瘤学杂志,2014,20(04):270-275.]
[14]Wen G,Zhang YJ,Zhu YJ,et al.Predictive value of molecular subtyping for loco-regional recurrence in early breast cancer patients with one to three positive axillary lymph nodes[J].Chinese J Radiation Oncology,2013,22(2):89-93.[温戈,张玉晶,祝喻甲,等.分子分型对1-3个腋窝淋巴结转移早期乳腺癌患者局部或区域复发风险的预测价值[J].中华放射肿瘤学杂志,2013,22(2):89-93.]
[15]Pathmanathan N,Balleine RL.Ki67 and proliferation in breast cance[J].J Clin Pathol,2013,66(6):512-516.
[16]Yamamoto S,Ibusuki M,Yamamoto Y,et al.Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer spcimens[J].Breast Cancer,2013,20(3):262-270.